ALBUQUERQUE, N.M. — Dudley Sue Bock, 75, received the shocking news last July that she had a 70 percent blockage in one of the two arteries that provide blood to her brain.
In October, Bock became one of the first patients in the Southwestern U.S. to undergo a new stenting procedure at New Mexico Heart Institute that restored blood flow through carotid artery on the right side of her neck.
The procedure, called Transcarotid Artery Revascularization, or TCAR, is intended to lower the risk of stroke or heart attack, particularly in older patients, while patients are on the operating table, Heart Institute surgeons said.
“The question here is, is there any way to limit that stress on the heart, but keep the procedure as safe and effective” as conventional surgery, said Dr. Steve Henao, the Heart Institute’s chief of vascular surgery.
The Heart Institute is one of about 40 medical centers worldwide participating in a study to evaluate the effectiveness of TCAR, which was approved by the U.S. Food and Drug Administration in 2015 for use in patients at high risk of stroke.
Read More: https://www.abqjournal.com/981104/technology-3.html
Via: Albuquerque Journal
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models
Via: Yahoo! Finance
Outset Medical, a commercial-stage company delivering new technology into the $13 billion global dialysis market, today announced the appointment of Gus Castello as the company’s chief operating officer.
Via: The Hill
BY SEAN DUFFY, OPINION CONTRIBUTOR
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.
Via: ASN Kidney News
An interview with Leslie Trigg, President and CEO of Outset Medical
Silicon Valley venture pioneer Bill Draper will get a lifetime achievement award from the National Venture Capital Association next month.
Digital diabetes management company Omada Health has brought on federal policy veteran Lucia Savage as their new Chief Privacy and Regulatory Officer. Savage, who previously worked as Chief Privacy Officer at the Office of the National Coordinator for IT, will lead Omada’s legal and compliance team. In her new role, Savage will lead Omada’s regulatory strategy and ensure the privacy and security of the platform users’ personal health information. She will also work to advance Omada’s integration with EHRs and other patient record systems, in the aim to bring the company further into clinical processes.
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced it has enrolled and dosed the first patient in a Phase 1b clinical trial of its anti-DLL4/VEGF bispecific antibody (OMP-305B83) in combination with paclitaxel in patients with platinum-resistant ovarian cancer. OncoMed's anti-DLL4/VEGF bispecific antibody is designed to have anti-angiogenic, anti-cancer stem cell and immuno-modulatory activity.
Today’s medical therapy is tough competition, but new devices for use in CAS might tip the balance toward endovascular therapy, experts say.